tiprankstipranks
Advertisement
Advertisement

FHTX Stock Latest News

Maintaining Buy on Foghorn: Advancing FHD-909, Productive Discovery Engine, and Cash Runway Drive Attractive Risk–Reward Ahead of Key 2026 Catalyst
RatingsMaintaining Buy on Foghorn: Advancing FHD-909, Productive Discovery Engine, and Cash Runway Drive Attractive Risk–Reward Ahead of Key 2026 Catalyst
21d ago
FHTX
Buy Rating on Foghorn Therapeutics Driven by Lilly Partnership Catalyst, Advancing Degrader Pipeline, and Strengthened Cash Runway
PremiumRatings
Buy Rating on Foghorn Therapeutics Driven by Lilly Partnership Catalyst, Advancing Degrader Pipeline, and Strengthened Cash Runway
21d ago
FHTX
Foghorn Advances FHD-909 Trial and Strengthens Financial Position
PremiumCompany Announcements
Foghorn Advances FHD-909 Trial and Strengthens Financial Position
21d ago
8K
FHTX
Reigniting FHD-286: Chromatin-Targeted Synergy in Menin-Resistant AML Underpins Buy Rating on Foghorn
PremiumRatings
Reigniting FHD-286: Chromatin-Targeted Synergy in Menin-Resistant AML Underpins Buy Rating on Foghorn
23d ago
FHTX
Is FHTX a Buy, Before Earnings?
PremiumPre-Earnings
Is FHTX a Buy, Before Earnings?
30d ago
FHTX
Foghorn Therapeutics Names Veteran Executive as New CFO
PremiumCompany AnnouncementsFoghorn Therapeutics Names Veteran Executive as New CFO
1M ago
8K
FHTX
Foghorn Therapeutics appoints Maynard as Chief Financial Officer
Premium
The Fly
Foghorn Therapeutics appoints Maynard as Chief Financial Officer
1M ago
FHTX
Foghorn Therapeutics price target lowered to $12 from $14 at Jefferies
Premium
The Fly
Foghorn Therapeutics price target lowered to $12 from $14 at Jefferies
1M ago
FHTX
Jefferies Initiates Buy on Foghorn Therapeutics Driven by FHD‑909 Mid‑2026 Catalyst and Upside from Emerging EP300/CBP Degrader Pipeline
PremiumRatings
Jefferies Initiates Buy on Foghorn Therapeutics Driven by FHD‑909 Mid‑2026 Catalyst and Upside from Emerging EP300/CBP Degrader Pipeline
1M ago
FHTX
Foghorn Therapeutics Announces $50 Million Equity Financing
PremiumCompany Announcements
Foghorn Therapeutics Announces $50 Million Equity Financing
3M ago
8K
FHTX
3 ‘Strong Buy’ Stocks to Buy Today, 12/18/2025, According to Top Analysts
PremiumMarket News
3 ‘Strong Buy’ Stocks to Buy Today, 12/18/2025, According to Top Analysts
3M ago
FHTX
NUVL
Foghorn Therapeutics initiated with a Buy at BTIG
PremiumThe Fly
Foghorn Therapeutics initiated with a Buy at BTIG
3M ago
FHTX
Foghorn Therapeutics Appoints Interim CFO Jeff Sacher
PremiumCompany AnnouncementsFoghorn Therapeutics Appoints Interim CFO Jeff Sacher
4M ago
8K
FHTX
Promising Developments and Strategic Partnerships Position Foghorn Therapeutics for Growth: A Buy Rating by Laura Prendergast
Premium
Ratings
Promising Developments and Strategic Partnerships Position Foghorn Therapeutics for Growth: A Buy Rating by Laura Prendergast
4M ago
FHTX
Foghorn Therapeutics initiated with a Buy at Stifel
Premium
The Fly
Foghorn Therapeutics initiated with a Buy at Stifel
4M ago
LLY
FHTX
Strategic Drug Development and Scientific Rigor Drive Buy Rating for Foghorn Therapeutics
PremiumRatings
Strategic Drug Development and Scientific Rigor Drive Buy Rating for Foghorn Therapeutics
5M ago
FHTX
Foghorn Therapeutics Unveils Strategic Advancements with Lilly
PremiumCompany Announcements
Foghorn Therapeutics Unveils Strategic Advancements with Lilly
5M ago
8K
FHTX
Foghorn Therapeutics initiated with a Buy at Guggenheim
PremiumThe Fly
Foghorn Therapeutics initiated with a Buy at Guggenheim
5M ago
FHTX
Foghorn Therapeutics Reports Q3 2025 Financial Results
PremiumCompany Announcements
Foghorn Therapeutics Reports Q3 2025 Financial Results
5M ago
FHTX
Foghorn Therapeutics: Promising Pipeline and Strategic Collaborations Drive Buy Rating
PremiumRatingsFoghorn Therapeutics: Promising Pipeline and Strategic Collaborations Drive Buy Rating
5M ago
FHTX
Foghorn Therapeutics CFO Kristian Humer Resigns
Premium
Company Announcements
Foghorn Therapeutics CFO Kristian Humer Resigns
5M ago
8K
FHTX
Foghorn Therapeutics reports Q3 EPS (25c), consensus (30c)
Premium
The Fly
Foghorn Therapeutics reports Q3 EPS (25c), consensus (30c)
5M ago
FHTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >